Kelly Financial Services LLC Gilead Sciences, Inc. Transaction History

Kelly Financial Services LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 17, 2024	BUY	$71.58 - $87.29 $71 - $87	1 Added 6.25%	17 $1,000
Q2 2023 Jul 17, 2024	SELL	$76.01 - $86.7 $2,052 - $2,340	-27 Reduced 62.79%	16 $1.24 Million
Q1 2023 Jul 17, 2024	BUY	$77.31 - $88.08 $2,087 - $2,378	27 Added 168.75%	43 $3.56 Million
Q3 2022 Jul 17, 2024	BUY	$59.54 - $68.01 $59 - $68	1 Added 6.67%	16 $962,000
Q3 2021 Jul 17, 2024	SELL	$67.69 - $73.03 $77,843 - $83,984	-1,150 Reduced 98.71%	15 $1.04 Million
Q2 2021 Jul 17, 2024	BUY	$63.47 - $69.35 $72,863 - $79,613	1,148 Added 6752.94%	1,165 $17,000
Q1 2021 Jul 17, 2024	SELL	$60.0 - $68.46 $9,240 - $10,542	-154 Reduced 90.06%	17 $1.08 Million
Q4 2020 Jul 17, 2024	BUY	$56.65 - $64.55 $56 - $64	1 Added 0.59%	171 $9.94 Million
Q3 2020 Jul 17, 2024	SELL	$62.1 - $78.08 $621 - $780	-10 Reduced 5.56%	170 $10.8 Million
Q2 2020 Jul 17, 2024	BUY	$72.34 - $84.0 $1,302 - $1,512	18 Added 11.11%	180 $13.9 Million
Q1 2020 Jul 17, 2024	BUY	$62.63 - $80.22 $10,020 - $12,835	160 Added 8000.0%	162 $12.1 Million
Q4 2019 Jul 17, 2024	BUY	$61.62 - $67.78 $123 - $135	2 New	2 $131,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Kelly Financial Services LLC, based on Form 13F filings with the SEC.

Stay updated on Kelly Financial Services LLC with notifications on news.